VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Eli Lilly and Company1,366 enrolled

Overview

The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

1,366

Conditions

Postmenopausal Osteoporosis

Interventions

TeriparatideDRUG

Administered SC

RisedronateDRUG

Administered orally

PlaceboDRUG

Teriparatide arm placebo administered orally. Risedronate arm placebo administered SC.

Calcium

Eligibility

Sex: FEMALEMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal women with osteoporosis, as defined by low bone mineral density (BMD), i.e. anterior-posterior lumbar spine, total hip or femoral neck BMD ≥1.5 standard deviations below the average BMD for young, healthy, non-Hispanic, Caucasian women * A minimum of 2 moderate or 1 severe vertebral fragility fractures (confirmed by central reader) were required Exclusion Criteria: * Increased risk of osteosarcoma * History of unresolved skeletal diseases that affect bone metabolism * History of atypical subtrochanteric or diaphyseal femoral fractures * Abnormally high or low calcium levels * Abnormally high parathyroid hormone (PTH) levels * Severe vitamin D deficiency * Abnormal thyroid function not corrected by therapy * History of malignant neoplasms in the last 5 years * Active liver disease, clinical jaundice * Significant impairment of hepatic or renal function * History of nephro- or urolithiasis * Previous or planned kypho- or vertebroplasty * Active or risk for osteonecrosis of the jaw * Active or recent history of upper gastrointestinal disorders * Unable to stand or sit in the upright position for at least 30 minutes

Locations (103)

Outcomes

Primary Outcomes

Proportion of Participants With New Vertebral Fractures

The incidence of new vertebral fractures was assessed by quantitative vertebral morphometry measurements (QM) with qualitative visual semiquantitative grading (SQ) confirmation. A new vertebral fracture was diagnosed in a vertebra that was non-fractured at the baseline radiological examination. It was defined as a loss of vertebral body height of at least 20% and 4 mm from the baseline radiograph by vertebral QM, based upon placement of six points by a trained, central reader. Any fractures identified by QM were confirmed using SQ: if the vertebral body also had an increase of one or more severity grade, it was considered an incident vertebral fracture.

Time frame: Baseline through 24 Months

Secondary Outcomes

Proportion of Participants With Pooled New and Worsening Vertebral Fractures

Worsening of a pre-existing fracture was considered if the decrease in vertebral height was at least one severity grade in the semi-quantitative assessment, confirmed by a trained central reader, where vertebrae were graded as normal (SQ0) or as with mild (SQ1), moderate (SQ2), or severe (SQ3) fractures, defined as \~20 to 25% (mild), \~25 to 40% (moderate) or \~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 to L4).

Time frame: Baseline through 24 Months

Proportion of Participants With Pooled Clinical Vertebral and Non-Vertebral Fragility Fractures

A clinical vertebral fracture was defined as a new or worsening vertebral fracture, confirmed by radiography, that was associated with signs and symptoms highly suggestive of a vertebral fracture. All non-vertebral fractures that occurred and were diagnosed between visits required the confirmation by the site investigators after evaluating the original x-ray film(s), the radiology or surgical report. For clinical vertebral fractures, the final confirmation of the diagnosis required the centralized evaluation by a trained, independent reader.

Time frame: Baseline through 24 Months

Proportion of Participants With Non-Vertebral Fragility Fractures

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Vitamin DDRUG

Administered orally

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Birmingham, Alabama, United States

Concord, California, United States

Fresno, California, United States

Laguna Hills, California, United States

Lancaster, California, United States

Tustin, California, United States

Lakewood, Colorado, United States

Danbury, Connecticut, United States

Orlando, Florida, United States

Gainesville, Georgia, United States

...and 93 more locations

A non-vertebral fracture is a fracture at any of the following non-vertebral sites: clavicle, scapula, ribs, sternum, sacrum, coccyx, humerus, radius, ulna, carpus, pelvis, hip, femur, patella, tibia, fibula, ankle, calcaneus, tarsus, and metatarsal. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object were not considered fragility fractures but traumatic fractures.

Time frame: Baseline through 24 Months

Proportion of Participants With Major Non-Vertebral Fragility Fractures

A major non-vertebral fracture is a fracture at any of the following non-vertebral sites hip, radius, humerus, ribs, pelvis, tibia and femur. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving.

Time frame: Baseline through 24 Months

Proportion of Participants With New Moderate and/or Severe Vertebral Fractures

Vertebrae were graded as moderate (SQ2), or severe (SQ3) fractures, based on \~25 to 40% (moderate) or \~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 through L4).

Time frame: Baseline through 24 Months

Proportion of Participants With New Multiple (2 or More) Vertebral Fractures

Time frame: Baseline through 24 Months

Proportion of Participants With Pooled Fragility and Traumatic Non-Vertebral Fractures

Traumatic fractures were considered if resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object.

Time frame: Baseline through 24 Months

Change From Baseline to 24 Months Endpoint in Height

Time frame: Baseline, 24 Months

Change From Baseline to 24 Months Endpoint in Back Pain Using an 11-point Numerical Pain Rating Scale

Participants rated the worst back pain during the 24 hours preceding the visit at baseline and each post-baseline visit. An 11-point numerical back pain rating scale (rated from 0 = no back pain to 10 = worst possible back pain) was used.

Time frame: Baseline, 24 Months

Change From Baseline to 24 Months Endpoint in the European Quality of Life Questionnaire [EQ-5D-5L] (UK)

The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.59 to 1.0. A higher score indicates better health state.

Time frame: Baseline, 24 Months

Change From Baseline to 24 Months Endpoint in the European Quality of Life Questionnaire [EQ-5D-5L] (US)

The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United States (US) cross walk algorithm, with scores ranging from -0.11 to 1.0. A higher score indicates better health state.

Time frame: Baseline, 24 Months